CTIS2024-513200-34-00招募中1 期
Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids.A pilot, one-arm, open-label, prospective study: the MetNET-2 trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Adult patients (male or female, age > 18 years), Basal blood tests: - Counts of neutrophils in absolute value> 1.5 x 103 / L - Platelet count> 100 x 103 / L - Hemoglobin> 9 g/dl - Total Bilirubin <1.5 times the upper limit of normal - AST, ALT <2.5 times the upper limit of normal - Alkaline phosphatase <2.5 times the upper limit of normal - Values of serum creatinine <1.5 mg / dl. - CCr = 60 mL / min, ECOG performance status = 2, Life expectancy > 12 months, Written informed consent, Female subjects of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for at least 60 days after participation in the study. Acceptable methods of contraception include double barrier method [i.e. condom and occlusive cap (diaphragm or cervical/vault caps)] spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method., Male subjects with female partners of childbearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 60 days after participation in the study, Patient with advanced disease, not resectable. The evaluation of unresectable disease will be performed by surgeon of multidisciplinary Milan ENETS Center of Excellence tumour board of Fondazione IRCCS Istituto Nazionale dei Tumori Milano., Patients with a histologically documented diagnosis of advanced well differentiated (G1 and G2) GI or lung carcinoids, defined according to the last WHO Classification criteria for NET, Tumor tissue available for analysis, Measurable disease and disease progression in the 6 months before study inclusion (according to RECIST vs 1.1), documented and appropriate imaging, Patient who has received prior treatment with surgery or chemotherapy or somatostatin analogues or m-TOR inhibitors or other systemic antineoplastic/target therapies, Functioning or non-functioning NETs, Type-2 Diabetic or normoglycaemic patient, Documented Octreoscan/PET Ga uptake/IHC stain of SSTR2 receptor, within 6 months before study entry
排除标准
- •Surgery performed within 28 days prior to the beginning of study treatment, Patients with a condition of metabolic acidosis, acute or chronic, including ketoacitosi, History of POTUS (alcohol abuse), or habitual intake of alcohol (= 3 glasses of alcoholic drinks / day) sufficient to cause hepatotoxicity, Severe states of dehydration, Prolonged fasting, History of immunosuppression, including positive HIV test, Previous or concomitant oncological pathology, except: basal cell skin cancer, in situ, as long as every other cancer patient disease-free for at least 5 years, Serious neurological or psychiatric disorders, Pregnancy or lactation, Patients that do not use appropriate methods of contraception as specified in the inclusion criteria, Brain metastasis or spinal cord compression, Type-1 Diabetes, Clinically significant cardiovascular disease, such as cardiovascular accidents occurred in less than 6 months, unstable angina, congestive heart failure grade greater than or equal to II (according to the classification of the New York Heart Association NYHA) series cardiac arrhythmias that require treatment, Uncontrolled high blood pressure, atrial fibrillation, Cardio-vascular, lung, kidney or hepatic disorders not treated/controlled, Cirrhosis, acute hepatitis or chronic active hepatitis, Metabolic disorders, clinical examination or laboratory investigations which contraindicate the use of drugs to study, or patients at high risk of complications from the treatment, Active or uncontrolled severe infections
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORSprogressive well differentiated thoracic neuroendocrine tumorsMedDRA version: 20.0Level: PTClassification code 10007282Term: Carcinoid tumour pulmonarySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10037342Term: Pulmonary carcinoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10068115Term: Metastatic carcinoid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10068118Term: Metastatic carcinoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10052399Term: Neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005579-10-ITIPSEN S.P.A.40
Unknown
早期 1 期
The MetNET-2 TrialNeuroendocrine TumorsNCT02823691Fondazione IRCCS Istituto Nazionale dei Tumori, Milano20
进行中（未招募）
不适用
Maintenance treatment with Lanreotide in Patients with small cell lung cancer expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapySmall cell lung cancerEUCTR2011-005730-20-ITA.O. UNIVERSITARIA INTEGRATA DI VERONA134
已完成
2 期
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.Neuroendocrine TumoursNCT02698410Ipsen40
进行中（未招募）
1 期
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 dayswell differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumoursMedDRA version: 21.0 Level: PT Classification code 10052399 Term: Neuroendocrine tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005607-24-PLIpsen Innovation100